Charlotte Dravet

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Retrieved on: 
Wednesday, March 3, 2021
Research, Mental health, Teens, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Health, Neurological disorders, Clinical medicine, Epilepsy, Syndromes, Epilepsy syndromes, Lennox–Gastaut syndrome, LGS, Dravet syndrome, Lennox, Epilepsy-intellectual disability in females, Charlotte Dravet, Soticlestat (TAK-935/OV935), Dravet Syndrome and Lennox-Gastaut Syndrome, Ovid Therapeutics

Under the new exclusive agreement, all global rights to soticlestat have been secured by Takeda from Ovid.

Key Points: 
  • Under the new exclusive agreement, all global rights to soticlestat have been secured by Takeda from Ovid.
  • Ovid led global development of soticlestat through the successful demonstration of proof-of-concept in multiple rare epilepsies.
  • Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021.
  • Dravet syndrome and Lennox-Gastaut syndrome are types of developmental and epileptic encephalopathies (DEEs), a heterogeneous group of rare epilepsy syndromes.

Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

Retrieved on: 
Wednesday, November 25, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Neurological disorders, Epilepsy, Health, Medicine, Dravet syndrome, Sudden unexpected death in epilepsy, Epilepsy syndromes, Charlotte Dravet, STK-001, Phase 1/2a Clinical Study (MONARCH), Dravet Syndrome, Stoke Therapeutics

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life.

Key Points: 
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life.
  • Patients enrolled to date are representative of patients with Dravet syndrome, and data collected indicate that the selected cognition measures are valid and appropriate for use in patients with Dravet syndrome.
  • The primary endpoints are safety, tolerability and pharmacokinetic profile of STK-001 in Dravet syndrome patients.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.

Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023) - Attractive Orphan Drug Policies & Rising Strategic Alliances are Key Drivers - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 5, 2019
Health, Pharmaceutical, Neurological disorders, Medicine, Epilepsy, Sodium channels, Dravet syndrome, SMEI, Nav1.1, Epileptic seizure, Myoclonus, Dravet Syndrome Foundation, Charlotte Dravet

The "Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.
  • Currently, the U.S. and Europe are holding the potential growth for Dravet Syndrome market due to increasing R&D into new drug development for Dravet syndrome and approval for these drugs in these regions.
  • Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a severe kind of epilepsy which causes seizures.
  • Patients with Dravet syndrome are not able to produce sufficient levels of functional Nav1.1 sodium channel, preventing inhibitory neurons from firing properly.